| Revenue growth | 21% Q4 growth; full year up 17% surpassing ₹5,000cr. |
|---|---|
| Margins | EBITDA margin at 26% FY26; guiding for 27% in FY27. |
| Demand visibility | Strong domestic and US outlook; cautious on Middle East logistics. |
| Management confidence | High, despite logistical headwinds in Asia and Africa. |
Growth
Revenue grew 21% in Q4 and 17% for FY26; US generics led with 49% annual growth.
Outlook
FY27 guidance: revenue growth in 'high teens', EBITDA margin targeted at 27%, and capex of ₹400cr.
Risks
Asia business declined 10% in Q4 due to Red Sea logistical disruptions; rising freight and R&D costs.
Earnings Call filed with BSE, NSE: AJANTPHARM. Summary written with AI assistance from the document.
Ajanta Pharma Ltd: key numbers
- Share price
- ₹3,569.80
- Market cap
- ₹44,608 Cr
- Revenue (annual)
- ₹5,453 Cr
- Net profit (annual)
- ₹1,056 Cr
- P/E (TTM)
- 39.3×Sector 47.3×
- Promoter holding
- 63.48%-2.77% QoQ
- FII holding
- 7.68%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Ajanta Pharma Ltd
All →Ajanta Pharma Share Pledge
Aayush Agrawal (Trustee of Aayush Agrawal Trust) has released a pledge on 1,736,353 equity shares of Ajanta Pharma Limited. This follows loan repayment.
Ajanta Pharma Share Pledge
Promoter Aayush Agrawal Trust released pledge on 9.76 lakh shares and created a new pledge on 9.20 lakh shares of Ajanta Pharma Limited.
Ajanta Pharma Share Pledge
Promoter Ravi Agrawal, as trustee of Ravi Agrawal Trust, released a pledge on 54,796 equity shares of Ajanta Pharma Limited due to excess pledge.
Ajanta Pharma Earnings Call Transcript: Key Takeaways
Ajanta Pharma reports strong Q1 FY27 results, but management remains cautious about sustainability, guiding for normalization in the US and acknowledging geopolitical headwinds in Asia.
- Call
- Guides 18% growth
Ajanta Pharma Employee Stock Options
Ajanta Pharma Limited has allotted 23,400 equity shares following the exercise of employee stock options. Consequently, the company's paid-up share capital increased to Rs. 24.99 Crore.
Ajanta Pharma Dividend
Ajanta Pharma Limited has fixed August 5, 2026, as the record date. This date determines shareholder eligibility for the payment of the first interim dividend.